Business
Vivani Medical to Present at the Partnership Opportunities in Drug Delivery (PODD) Event and ThinkEquity Conference in October 2024
ALAMEDA, Calif.--(BUSINESS WIRE)-- Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing
About this update from Vivani Medical, Inc.
[{"type":"text","content":" ALAMEDA, Calif.--(BUSINESS WIRE)--\nVivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative biopharmaceutical company developing miniaturized, ultra long-acting drug implants, announced today that it will present at two upcoming events in October: (1) Partnership Opportunities in Drug Delivery (PODD), taking place in Boston on October 28 and 29, 2024 and (2) the ThinkEquity Conference, taking place in New York on October 30, 2024.\n\nEvent details are as follows:\n\nPartnership Opportunities in Drug Delivery (PODD) Event\nPanel (Track 1): Targeted and Long Acting Delivery; Sustained Release Innovations to Reduce Patient Burden\nDate: Tuesday, October 29, 2024\nTime: 3:35 p.m. - 4:05 p.m. Eastern Time\nLocation: Westin Boston Seaport, 425 Summer Street, Boston, MA 02210\n\nDr. Adam Mendelsohn, Vivani’s Chief Executive Officer and other industry representatives will participate on the panel discussion which will be moderated by Stephen Buckley, Ph.D., Vice President, Advanced Drug Delivery at Novo Nordisk. More information about the panel and PODD event can be found at https://poddconference.com/.\n\nThinkEquity Conference\nPresentation Date: Wednesday, October 30, 2024\nPresentation Time: 2:30 p.m. Eastern Time\nLocation: The Mandarin Oriental Hotel, 80 Columbus Circle, New York, 10023\n\nDr. Mendelsohn will provide a Company related update. A webcast of the Vivani ThinkEquity Conference presentation will be available on the Investors page of the Vivani corporate website and at the following link: https://wsw.com/webcast/tep25/vani/1677024.\n\nMore information about the ThinkEquity Conference, including registration information, can be found at https://www.think-equity.com/thinkequity-conference.\n\nAbout Vivani Medical, Inc.\n\nLeveraging its proprietary NanoPortalTM platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and potentially to improve patient tolerance to their medication. Vivani’s lead program, NPM-115, utilizes a miniature, six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in obese or overweight individuals. Vivani’s emerging pipeline also includes the NPM-139 (semaglutide) implant which is also under development for chronic weight ma...